1. Home
  2. CVKD
  3. CVKD News

Latest Cadrenal Therapeutics Inc. (CVKD) News on July 12, 2025

Cadrenal Therapeutics Highlights New Research on Anticoagulation Burden for LVAD Patients
CVKD

Business Wire

a month ago

Cadrenal Therapeutics Highlights New Research on Anticoagulation Burden for LVAD Patients

Cadrenal Therapeutics to Engage Potential Partners at BIO International Convention 2025
CVKD

Business Wire

a month ago

Cadrenal Therapeutics to Engage Potential Partners at BIO International Convention 2025

CVKD

Zacks Small Cap Research

2 months ago

CVKD: Preparations Continue for Phase 3 Trial of Tecarfarin…

Cadrenal Therapeutics Announces Tecarfarin Manufacturing Progress in Support of Clinical Trial Readiness
CVKD

Business Wire

2 months ago

Cadrenal Therapeutics Announces Tecarfarin Manufacturing Progress in Support of Clinical Trial Readiness

Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update
CVKD

Business Wire

2 months ago

Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update

Is Cadrenal Therapeutics (NASDAQ:CVKD) In A Good Position To Deliver On Growth Plans?
CVKD

Simply Wall St.

3 months ago

Is Cadrenal Therapeutics (NASDAQ:CVKD) In A Good Position To Deliver On Growth Plans?

Cadrenal Therapeutics Participates in Key Medical and Business Development Conferences
CVKD

Business Wire

3 months ago

Cadrenal Therapeutics Participates in Key Medical and Business Development Conferences

CVKD

Zacks Small Cap Research

3 months ago

CVKD: Preparing for Phase 3 Trial of Tecarfarin…

Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin
CVKD

Business Wire

4 months ago

Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin

CVKD

Zacks Small Cap Research

4 months ago

CVKD: Collaborating with Abbott for Pivotal Phase 3 Trial…

Cadrenal and Abbott sign agreement for LVAD trial of tecarfarin
CVKD

Medical Device Network

4 months ago

Cadrenal and Abbott sign agreement for LVAD trial of tecarfarin

CVKD

MT Newswires

4 months ago

Cadrenal Therapeutics to Collaborate With Abbott on Trial of Heart Device Drug

Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3™ LVAD
CVKD

Business Wire

4 months ago

Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3™ LVAD

Cadrenal Therapeutics Announces Chief Medical Officer Transition to Advance Clinical Development of Tecarfarin
CVKD

Business Wire

5 months ago

Cadrenal Therapeutics Announces Chief Medical Officer Transition to Advance Clinical Development of Tecarfarin

Cadrenal Therapeutics to Present at BIO CEO & Investor Conference
CVKD

Business Wire

5 months ago

Cadrenal Therapeutics to Present at BIO CEO & Investor Conference

Cadrenal Therapeutics to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
CVKD

Business Wire

6 months ago

Cadrenal Therapeutics to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

Cadrenal Therapeutics Provides 2024 Year-End Company Update, Reinforcing Clinical Development Plan for Tecarfarin in LVAD and Other Rare Cardiovascular Indications
CVKD

Business Wire

6 months ago

Cadrenal Therapeutics Provides 2024 Year-End Company Update, Reinforcing Clinical Development Plan for Tecarfarin in LVAD and Other Rare Cardiovascular Indications

Cadrenal Therapeutics Gears Up for the 43rd Annual J.P. Morgan Healthcare Conference Week with Event Participation and Investor/Partner Meetings
CVKD

Business Wire

7 months ago

Cadrenal Therapeutics Gears Up for the 43rd Annual J.P. Morgan Healthcare Conference Week with Event Participation and Investor/Partner Meetings

CVKD

Zacks Small Cap Research

8 months ago

CVKD: Recent Financings Raise $9.8 Million…

Cadrenal Therapeutics Named Anticoagulation Therapy Company of the Year by Pharma Tech Outlook
CVKD

PR Newswire

8 months ago

Cadrenal Therapeutics Named Anticoagulation Therapy Company of the Year by Pharma Tech Outlook

CADRENAL THERAPEUTICS HIGHLIGHTS PRESENTATION AT EUROPEAN ASSOCIATION FOR CARDIO-THORACIC SURGERY (EACTS) MEDICAL CONGRESS
CVKD

PR Newswire

8 months ago

CADRENAL THERAPEUTICS HIGHLIGHTS PRESENTATION AT EUROPEAN ASSOCIATION FOR CARDIO-THORACIC SURGERY (EACTS) MEDICAL CONGRESS

CADRENAL THERAPEUTICS PROVIDES THIRD-QUARTER CORPORATE UPDATE
CVKD

PR Newswire

8 months ago

CADRENAL THERAPEUTICS PROVIDES THIRD-QUARTER CORPORATE UPDATE

Cadrenal Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds
CVKD

PR Newswire

8 months ago

Cadrenal Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds

We're Keeping An Eye On Cadrenal Therapeutics' (NASDAQ:CVKD) Cash Burn Rate
CVKD

Simply Wall St.

8 months ago

We're Keeping An Eye On Cadrenal Therapeutics' (NASDAQ:CVKD) Cash Burn Rate

Cadrenal Therapeutics Raises $5.1 Million via At-The-Market Facility
CVKD

PR Newswire

9 months ago

Cadrenal Therapeutics Raises $5.1 Million via At-The-Market Facility

CADRENAL THERAPEUTICS JOINS CORPORATE COUNCIL OF ANTICOAGULATION FORUM
CVKD

PR Newswire

9 months ago

CADRENAL THERAPEUTICS JOINS CORPORATE COUNCIL OF ANTICOAGULATION FORUM

Cadrenal Therapeutics to Participate in Lytham Partners Fall 2024 Investor Conference
CVKD

PR Newswire

10 months ago

Cadrenal Therapeutics to Participate in Lytham Partners Fall 2024 Investor Conference

CVKD

Zacks Small Cap Research

10 months ago

CVKD: New Blood Thinner Ready for Phase 3; Initiating Coverage of Cadrenal Therapeutics, Inc…

Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing
CVKD

ACCESSWIRE

10 months ago

Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing

CVKD

MT Newswires

a year ago

Cadrenal Therapeutics to Meet FDA in September on Tecarfarin Trial

Cadrenal Therapeutics Announces Upcoming Type-B FDA Meeting in September to Discuss Tecarfarin Trial in LVAD Patients
CVKD

PR Newswire

a year ago

Cadrenal Therapeutics Announces Upcoming Type-B FDA Meeting in September to Discuss Tecarfarin Trial in LVAD Patients

Published Findings Highlight Tecarfarin's Potential and Reinforce Need for Better Anticoagulation Therapy in LVAD Patients
CVKD

PR Newswire

a year ago

Published Findings Highlight Tecarfarin's Potential and Reinforce Need for Better Anticoagulation Therapy in LVAD Patients

Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now
CVKD

GlobeNewswire

a year ago

Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now

CVKD

MT Newswires

a year ago

Cadrenal Therapeutics to Implement 1-for-15 Reverse Stock Split

Cadrenal Therapeutics to Present at Upcoming Investor Conferences
CVKD

PR Newswire

a year ago

Cadrenal Therapeutics to Present at Upcoming Investor Conferences

Cadrenal Therapeutics, Inc. (CVKD): A New Penny Stock to Buy Now
CVKD

Insider Monkey

a year ago

Cadrenal Therapeutics, Inc. (CVKD): A New Penny Stock to Buy Now

Cadrenal Therapeutics Provides Second Quarter 2024 Corporate Update
CVKD

PR Newswire

a year ago

Cadrenal Therapeutics Provides Second Quarter 2024 Corporate Update

CVKD: Cadrenal Therapeutics and Abbott Collaborate on Novel Anticoagulant for LVAD Patients
CVKD

Zacks Small Cap Research

a year ago

CVKD: Cadrenal Therapeutics and Abbott Collaborate on Novel Anticoagulant for LVAD Patients

CVKD

MT Newswires

a year ago

Cadrenal Therapeutics in Talks With Abbott to Study Tecarfarin in Patients With LVAD

Cadrenal Therapeutics and Abbott Initiate Collaborative Effort to Advance Novel Anticoagulant Tecarfarin for Patients with LVADs
CVKD

PR Newswire

a year ago

Cadrenal Therapeutics and Abbott Initiate Collaborative Effort to Advance Novel Anticoagulant Tecarfarin for Patients with LVADs

Cadrenal Therapeutics to Present at the Emerging Growth Conference on July 18, 2024
CVKD

PR Newswire

a year ago

Cadrenal Therapeutics to Present at the Emerging Growth Conference on July 18, 2024

Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now
CVKD

GlobeNewswire

a year ago

Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now

Presenting on the Emerging Growth Conference 72 Day 2 on June 13 Register Now
CVKD

GlobeNewswire

a year ago

Presenting on the Emerging Growth Conference 72 Day 2 on June 13 Register Now

Cadrenal Therapeutics to Present at the Emerging Growth Conference on June 12, 2024
CVKD

PR Newswire

a year ago

Cadrenal Therapeutics to Present at the Emerging Growth Conference on June 12, 2024

Presenting on the Emerging Growth Conference 72 Day 1 on June 12 Register Now
CVKD

GlobeNewswire

a year ago

Presenting on the Emerging Growth Conference 72 Day 1 on June 12 Register Now

Cadrenal Therapeutics Highlights Presentation of New Trial Data at ISHLT Conference Demonstrating the Importance of Anticoagulation Quality in LVAD Patients
CVKD

PR Newswire

a year ago

Cadrenal Therapeutics Highlights Presentation of New Trial Data at ISHLT Conference Demonstrating the Importance of Anticoagulation Quality in LVAD Patients

Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024
CVKD

PR Newswire

a year ago

Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024

Cadrenal Therapeutics Provides First Quarter 2024 Corporate Update
CVKD

PR Newswire

a year ago

Cadrenal Therapeutics Provides First Quarter 2024 Corporate Update

Favourable Signals For Cadrenal Therapeutics: Numerous Insiders Acquired Stock
CVKD

Simply Wall St.

a year ago

Favourable Signals For Cadrenal Therapeutics: Numerous Insiders Acquired Stock

Cadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024
CVKD

PR Newswire

a year ago

Cadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024

Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial Hearts
CVKD

PR Newswire

a year ago

Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial Hearts

Cadrenal Therapeutics Provides Fourth Quarter 2023 Corporate Update
CVKD

PR Newswire

a year ago

Cadrenal Therapeutics Provides Fourth Quarter 2023 Corporate Update

Cadrenal Therapeutics to Participate at Technology and Heart Failure Therapeutics (THT) Conference
CVKD

PR Newswire

a year ago

Cadrenal Therapeutics to Participate at Technology and Heart Failure Therapeutics (THT) Conference

Cadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer in Advance of Tecarfarin Phase 3 Pivotal Trial
CVKD

PR Newswire

a year ago

Cadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer in Advance of Tecarfarin Phase 3 Pivotal Trial

Cadrenal Therapeutics Highlights Publication of Peer-Reviewed Article Supporting Need for New Anticoagulation Therapy for Patients with Certain Medical Conditions
CVKD

PR Newswire

a year ago

Cadrenal Therapeutics Highlights Publication of Peer-Reviewed Article Supporting Need for New Anticoagulation Therapy for Patients with Certain Medical Conditions

Here's Why We're Not Too Worried About Cadrenal Therapeutics' (NASDAQ:CVKD) Cash Burn Situation
CVKD

Simply Wall St.

a year ago

Here's Why We're Not Too Worried About Cadrenal Therapeutics' (NASDAQ:CVKD) Cash Burn Situation

Allspring Closed-End Funds Declare Monthly Distributions
CVKD

PR Newswire

a year ago

Allspring Closed-End Funds Declare Monthly Distributions

CVKD

Business Wire

a year ago

Mogo to Participate in the KBW Fintech & Payments Conference

Cadrenal Therapeutics to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024
CVKD

PR Newswire

a year ago

Cadrenal Therapeutics to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024

Calculating The Intrinsic Value Of Rent the Runway, Inc. (NASDAQ:RENT)
CVKD

Simply Wall St.

a year ago

Calculating The Intrinsic Value Of Rent the Runway, Inc. (NASDAQ:RENT)

GSI Technology to Announce Fiscal Third Quarter 2024 Results on January 25, 2024
CVKD

GlobeNewswire

2 years ago

GSI Technology to Announce Fiscal Third Quarter 2024 Results on January 25, 2024

CVKD

Business Wire

2 years ago

Mogo Portfolio Company WonderFi Provides Corporate Update

Cadrenal Therapeutics to Present at the Biotech Showcase on January 8, 2024 Alongside the J.P. Morgan Annual Healthcare Conference
CVKD

PR Newswire

2 years ago

Cadrenal Therapeutics to Present at the Biotech Showcase on January 8, 2024 Alongside the J.P. Morgan Annual Healthcare Conference

Assertio Holdings, Inc. Announces Leadership Transition
CVKD

GlobeNewswire

2 years ago

Assertio Holdings, Inc. Announces Leadership Transition

CVKD

Business Wire

2 years ago

Mogo’s Digital Payments Subsidiary, Carta Worldwide, Reports 36% Increase in Payments Volume in 2023 to $9.9 Billion

CVKD

Business Wire

2 years ago

Mogo repurchases 4.4% of outstanding shares since June 2022

Elicio Therapeutics Announces $7.0 Million Private Placement Financing
CVKD

GlobeNewswire

2 years ago

Elicio Therapeutics Announces $7.0 Million Private Placement Financing

Noble Capital Markets Initiates Coverage on Cadrenal Therapeutics with Outperform Rating and US$4.00 Price Target
CVKD

PR Newswire

2 years ago

Noble Capital Markets Initiates Coverage on Cadrenal Therapeutics with Outperform Rating and US$4.00 Price Target

Casterra Appoints New CEO and Expands Team to Drive Growth and Innovation
CVKD

PR Newswire

2 years ago

Casterra Appoints New CEO and Expands Team to Drive Growth and Innovation

Fossil Group (NASDAQ:FOSL) adds US$10m to market cap in the past 7 days, though investors from five years ago are still down 90%
CVKD

Simply Wall St.

2 years ago

Fossil Group (NASDAQ:FOSL) adds US$10m to market cap in the past 7 days, though investors from five years ago are still down 90%

Largo Provides Update on the Ongoing Exploration Program Surrounding its Maracás Menchen Mine in Brazil
CVKD

Business Wire

2 years ago

Largo Provides Update on the Ongoing Exploration Program Surrounding its Maracás Menchen Mine in Brazil

Progressive Care's PharmcoRx Pharmacies Expands Medicare Advantage Over-the-Counter Benefits Acceptance Program Through New Agreement with ProHealth Connect
CVKD

PR Newswire

2 years ago

Progressive Care's PharmcoRx Pharmacies Expands Medicare Advantage Over-the-Counter Benefits Acceptance Program Through New Agreement with ProHealth Connect

Cadrenal Therapeutics Engages The Sage Group to Advance Tecarfarin's Late-Stage Development and Commercialization
CVKD

PR Newswire

2 years ago

Cadrenal Therapeutics Engages The Sage Group to Advance Tecarfarin's Late-Stage Development and Commercialization

Safety Shot Sells Out on First Day Online at www.DrinkSafetyShot.com
CVKD

GlobeNewswire

2 years ago

Safety Shot Sells Out on First Day Online at www.DrinkSafetyShot.com

Nyxoah Announces Real World Case Series Demonstrating Positive Results in Treating CCC Patients with Genio®
CVKD

GlobeNewswire

2 years ago

Nyxoah Announces Real World Case Series Demonstrating Positive Results in Treating CCC Patients with Genio®

Actinium to Highlight Broad Potential of Targeted Radiotherapies Iomab-B and Actimab-A for Relapsed or Refractory and Elderly Acute Myeloid Leukemia Patients at the 65th ASH Annual Meeting & Exposition
CVKD

PR Newswire

2 years ago

Actinium to Highlight Broad Potential of Targeted Radiotherapies Iomab-B and Actimab-A for Relapsed or Refractory and Elderly Acute Myeloid Leukemia Patients at the 65th ASH Annual Meeting & Exposition

Cadrenal Therapeutics to Present at the NobleCon 19 Conference on December 4, 2023
CVKD

PR Newswire

2 years ago

Cadrenal Therapeutics to Present at the NobleCon 19 Conference on December 4, 2023

OSS Appoints Technology and Defense Industry Executive, Mitchell H. Herbets, to Board of Directors
CVKD

GlobeNewswire

2 years ago

OSS Appoints Technology and Defense Industry Executive, Mitchell H. Herbets, to Board of Directors

Positive Signs As Multiple Insiders Buy Design Therapeutics Stock
CVKD

Simply Wall St.

2 years ago

Positive Signs As Multiple Insiders Buy Design Therapeutics Stock

Shareholders in Dyadic International (NASDAQ:DYAI) are in the red if they invested three years ago
CVKD

Simply Wall St.

2 years ago

Shareholders in Dyadic International (NASDAQ:DYAI) are in the red if they invested three years ago

ProMIS Neurosciences Announces Third Quarter 2023 Financial Results and Recent Highlights
CVKD

GlobeNewswire

2 years ago

ProMIS Neurosciences Announces Third Quarter 2023 Financial Results and Recent Highlights

SKYX Platforms Corp. to Host Investor Update Call Today, Monday, November 13th at 4:30 p.m. Eastern Time
CVKD

ACCESSWIRE

2 years ago

SKYX Platforms Corp. to Host Investor Update Call Today, Monday, November 13th at 4:30 p.m. Eastern Time

Mogo Inc. (NASDAQ:MOGO) Q3 2023 Earnings Call Transcript
CVKD

Insider Monkey

2 years ago

Mogo Inc. (NASDAQ:MOGO) Q3 2023 Earnings Call Transcript

Inogen (INGN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
CVKD

Zacks

2 years ago

Inogen (INGN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Cadrenal Therapeutics Provides Third Quarter 2023 Corporate Update
CVKD

PR Newswire

2 years ago

Cadrenal Therapeutics Provides Third Quarter 2023 Corporate Update

Nephros Announces Results for Quarter Ended September 30, 2023
CVKD

GlobeNewswire

2 years ago

Nephros Announces Results for Quarter Ended September 30, 2023

CVKD

Business Wire

2 years ago

Wag! Reports Record Third Quarter 2023 Results

Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
CVKD

PR Newswire

2 years ago

Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results

Bakkt to Participate in Oppenheimer's 6th Blockchain & Digital Assets Summit
CVKD

Business Wire

2 years ago

Bakkt to Participate in Oppenheimer's 6th Blockchain & Digital Assets Summit

Share on Social Networks: